Myriad Genetics, Inc. (LON:0K3W)

Market Cap	1.02B
Revenue (ttm)	614.49M
Net Income (ttm)	-86.55M
Shares Out	n/a
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	674
Average Volume	253
Open	14.50
Previous Close	14.22
Day's Range	14.50 - 15.13
52-Week Range	14.50 - 24.13
Beta	1.78
RSI	64.50
Earnings Date	Feb 25, 2025

About Myriad Genetics

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or sus...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1992
• Employees: 2,700
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K3W

Financial Performance

In 2023, Myriad Genetics's revenue was $753.20 million, an increase of 11.03% compared to the previous year's $678.40 million. Losses were -$263.30 million, 135.1% more than in 2022.

Financial numbers in USD